The Conventional Wisdom
Your compliance team managing OTC derivatives might be celebrating the European Supervisory Authorities' proposed amendments to bilateral margin requirements. The logic seems straightforward: if counterparties below the €8 billion threshold no longer need to exchange initial margin on existing contracts, you've eliminated a significant operational burden. Less collateral management, fewer daily calculations, reduced documentation. Your team can redirect resources to other priorities.
This narrative has gained traction since the ESAs submitted their final report to the European Commission. Industry groups requested these changes to reduce compliance costs, and regulators listened. The amendments align EU requirements with other jurisdictions, creating a cleaner cross-border framework. What's not to like?
Why This View Is Incomplete
Here's the problem: reducing margin requirements doesn't reduce counterparty credit risk. It just changes who bears it.
When you stop exchanging initial margin with a counterparty, you haven't made that relationship safer. You've made an explicit decision to accept unsecured exposure. The €8 billion threshold was never a measure of credit quality or operational resilience. It's an arbitrary line that determines whether you post collateral, not whether you should worry about default risk.
Your third-party risk program shouldn't conflate regulatory relief with risk reduction. If a counterparty posed material credit exposure when you were exchanging margin last month, they pose the same exposure today. The regulatory framework has changed; the underlying risk hasn't.
The Evidence
Consider what the amendments actually do. Under the current framework, counterparties below the threshold are exempt from exchanging initial margin on new contracts but continue posting margin on existing positions. The proposed changes extend that exemption to existing contracts as well.
This creates a specific operational dynamic: you're now holding unhedged exposure on positions that were previously collateralized. Your mark-to-market exposure on those contracts hasn't disappeared. You've simply removed the daily margin calls that adjusted for price movements.
The ESAs framed these amendments as supporting "simplification and burden reduction" and achieving "greater consistency with the treatment applied in other jurisdictions." Both statements are accurate from a regulatory perspective. But consistency across jurisdictions doesn't mean the underlying counterparty risk has been harmonized or reduced. It means you're all accepting the same exposure without the same protections.
Look at your vendor risk profiles for counterparties near that €8 billion threshold. The financial metrics that matter for credit assessment haven't changed: leverage ratios, liquidity coverage, operational stability, concentration risk. A counterparty's ability to meet obligations during market stress isn't improved by regulatory relief.
What to Do Instead
Treat margin relief as a capital allocation decision, not a risk management win. Here's how:
Reassess your counterparty exposure limits. If you're no longer receiving initial margin, you're accepting higher unsecured exposure. Your credit limits should reflect that change. For counterparties where you previously relied on margin to mitigate tail risk, you need compensating controls: tighter concentration limits, more frequent financial reviews, or enhanced monitoring of their own derivative portfolios.
Update your vendor risk profiles with margin status as a control variable. Don't just note whether a counterparty is above or below the threshold. Document whether you're exchanging margin, why, and how that decision affects your exposure calculations. When you conduct ongoing vendor monitoring, track changes in their aggregate notional exposure across all counterparties. A firm below €8 billion today might cross that threshold next quarter.
Revisit your collateral management infrastructure before you decommission it. The operational burden of managing margin calls is real, but the systems and processes you built serve a purpose beyond regulatory compliance. If you've developed automated workflows for calculating exposure, calling collateral, and resolving disputes, those capabilities have value in stress scenarios. Mothball them if you must, but don't dismantle them entirely.
Stress-test your portfolio assuming no margin. Model what happens to your uncollateralized exposure during a significant market dislocation. The 2008 financial crisis and the March 2020 volatility spike both demonstrated how quickly OTC derivative positions can move against you. Initial margin exists because unsecured exposure in derivatives can crystallize faster than traditional credit exposures.
Align your internal risk appetite with the regulatory change. Your board or risk committee approved risk tolerances based on a framework that included margin requirements. If those requirements are now optional for a portion of your portfolio, you need explicit governance around which counterparties warrant continued margin exchange and which don't. This isn't a compliance decision; it's a risk appetite decision.
When the Conventional Wisdom Is Right
The ESAs' amendments do create legitimate efficiency gains in specific circumstances. If you're managing a portfolio of standardized derivatives with highly rated counterparties who maintain strong capital positions, the operational cost of margin management may genuinely outweigh the risk reduction it provides. For these relationships, regulatory relief translates to real cost savings without materially increasing risk.
Cross-border consistency also matters. If you're a multinational institution managing counterparties across multiple jurisdictions, having aligned margin requirements reduces operational complexity. You're not maintaining parallel frameworks or explaining to business units why the same counterparty requires margin in one jurisdiction but not another.
And for counterparties well below the threshold with minimal derivative activity, the amendments remove disproportionate compliance burden. A regional bank with €2 billion in aggregate notional exposure probably doesn't warrant the same margin infrastructure as a global derivatives dealer.
The key is recognizing when you fit these profiles and when you don't. Regulatory relief is an opportunity to optimize your risk management framework, not an excuse to reduce oversight. Your compliance burden may be lighter, but your counterparty credit risk hasn't changed. Manage it accordingly.
